Sign In
Buy INSM
$103.86
+0.130 (+0.125%)
At Close: Jun 03, 2026
Insmed (INSM) Reports Q1 Loss, Lags Revenue Estimates
09:16am, Thursday, 09'th May 2024
Insmed (INSM) came out with a quarterly loss of $1.06 per share versus the Zacks Consensus Estimate of a loss of $1.22. This compares to loss of $1.17 per share a year ago.
Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update
07:00am, Thursday, 09'th May 2024
— ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $75.5 Million for the First Quarter of 2024, Reflecting 16% Annual Growth Over the First Quarter of 2023— —Company Reports
Should You Buy Insmed (INSM) Ahead of Earnings?
11:21am, Wednesday, 08'th May 2024
Insmed (INSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Insmed To Present at the BofA Securities Health Care Conference 2024
08:00am, Tuesday, 07'th May 2024
BRIDGEWATER, N.J. , May 7, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, t
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
08:00am, Friday, 03'rd May 2024
BRIDGEWATER, N.J. , May 3, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, t
Insmed (INSM) Expected to Beat Earnings Estimates: Should You Buy?
11:06am, Thursday, 02'nd May 2024
Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024
08:00am, Thursday, 25'th Apr 2024
BRIDGEWATER, N.J. , April 25, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases,
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
08:00am, Friday, 05'th Apr 2024
BRIDGEWATER, N.J. , April 5, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases,
Insmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference
04:05pm, Wednesday, 27'th Mar 2024
—Additional Data from ARISE Study Evaluating the Impact of ARIKAYCE on Microbiologic Outcomes in Patients with Newly Diagnosed or Recurrent MAC Lung Disease to be Presented as Late-Breaker— —Dat
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
08:00am, Tuesday, 05'th Mar 2024
BRIDGEWATER, N.J. , March 5, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases,
Insmed To Present at Three March Conferences
08:00am, Thursday, 29'th Feb 2024
BRIDGEWATER, N.J. , Feb. 29, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases,
Insmed Incorporated (INSM) Q4 2023 Earnings Call Transcript
01:00pm, Thursday, 22'nd Feb 2024
Insmed Incorporated (INSM) Q4 2023 Earnings Call Transcript
Insmed (INSM) Reports Q4 Loss, Misses Revenue Estimates
09:10am, Thursday, 22'nd Feb 2024
Insmed (INSM) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $1.20 per share a year ago.
Insmed Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Business Update
07:00am, Thursday, 22'nd Feb 2024
—Topline Data from the Phase 3 ASPEN Trial of Brensocatib in Adult Patients with Bronchiectasis Remain on Track to Read Out in the Latter Part of Second-Quarter 2024— —Enrollment in the Phase 2
Insmed (INSM) Expected to Beat Earnings Estimates: Should You Buy?
11:06am, Thursday, 15'th Feb 2024
Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
